产品
编 号：F186536
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 156586-89-9
产品详情
生物活性：
Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research.
体内研究：
Edrecolomab (intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation) treatment inhibits tumor growth in the HT-29 nude mouse model.Animal Model:Male nu/nu mice injected with HT-29 colon carcinoma cells
Dosage:30 μg/dose
Administration:Intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation
Result:Inhibited tumor growth with a number of significant readings (p≤0.05).
体外研究：
Edrecolomab (0-100 μg/mL; 20 h) shows moderate antibody-dependent cellular cytotoxicity (ADCC).
Edrecolomab (Panorex) is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, expressed on epithelial tissues and on various carcinomas. Edrecolomab shows anti-tumor activity and can be used in colorectal carcinoma research.
体内研究：
Edrecolomab (intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation) treatment inhibits tumor growth in the HT-29 nude mouse model.Animal Model:Male nu/nu mice injected with HT-29 colon carcinoma cells
Dosage:30 μg/dose
Administration:Intravenous injection; 30 μg/dose; day 1, 4 and 7 after tumor-cell inoculation
Result:Inhibited tumor growth with a number of significant readings (p≤0.05).
体外研究：
Edrecolomab (0-100 μg/mL; 20 h) shows moderate antibody-dependent cellular cytotoxicity (ADCC).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备